Dr Reddy's Laboratories Limited

Sector: Pharmaceuticals  |  HQ: Hyderabad, Telangana  |  Founded: 1984  |  Employees: ~25,800

Listed as: NSE / BSE listed; Nifty 50 constituent; ADR on NYSE  |  NSE / BSE / NYSE  |  Ticker: DRREDDY.NS  |  Website →

Key people

• K. Satish Reddy (Chairman)
• G. V. Prasad (Co-Chairman and MD)
• Erez Israeli (CEO)

Company overview

Dr Reddy's Laboratories Limited is one of India's largest pharmaceutical companies and a global generics and biosimilars leader. Founded in 1984 by Dr Anji Reddy in Hyderabad, the company is headquartered in Hyderabad and operates 22 manufacturing facilities globally. FY25 consolidated revenue was approximately USD 3.6 billion (₹30,000 crore) with PAT of ₹5,650 crore. The company has a meaningful US generics franchise, an emerging biosimilars portfolio (Reditux, Cresp, Versavo), a strong India domestic branded generics business, and is one of the few Indian pharma companies with an ADR listed on the NYSE.

Business model

Dr Reddy's operates three reporting segments. Global Generics is the largest with US generics, Europe generics, India domestic formulations, and Emerging Markets contributing. The Pharmaceutical Services and Active Ingredients (PSAI) segment is the API and contract manufacturing business serving external customers. The Proprietary Products segment is the smaller specialty branded business with select dermatology and biosimilars launches.

Operating segments

Recent developments

May 21, 2026

Dr. Reddy's Laboratories is executing an aggressive Semaglutide franchise expansion across geographies. The company received SEC approval to manufacture and market oral Semaglutide tablets [9] and, following Delhi High Court clearance to manufacture and export the drug [10], launched a generic Semaglutide injection in Canada under the brand name Obeda® [2], with the injectable formulation also rolling out commercially [8]. This positions the company to capture share in the high-growth GLP-1 market. However, financial performance disappointed in the recent period: Dr. Reddy's missed EPS estimates by 16%, prompting analysts to revise their forecasts downward [4]. The stock saw heightened volatility, hitting a 10% upper circuit in late April [6], suggesting market uncertainty around the earnings miss versus the promising Semaglutide pipeline. Management is actively engaging investors through scheduled meets in May–June [5] to address these dynamics and outline the growth trajectory.

Sources (7)

1. Dr Reddy's Laboratories launches generic Semaglutide injection in Canada - Business Standard · Business Standard · Sat, 16 May 2026
2. Earnings Miss: Dr. Reddy's Laboratories Limited Missed EPS By 16% And Analysts Are Revising Their Forecasts - simplywall.st · simplywall.st · Fri, 15 May 2026
3. Dr. Reddy's Schedules Investor Meets in May-June - scanx.trade · scanx.trade · Sat, 16 May 2026
4. Why did Dr Reddy’s Laboratories shares hit the 10% upper circuit today? - Trade Brains · Trade Brains · Thu, 23 Apr 2026
5. Dr. Reddy’s Laboratories (RDY) Announces Rollout of Injectable Semaglutide Under Brand Name Obeda® - Yahoo Finance · Yahoo Finance · Fri, 24 Apr 2026
6. Dr Reddy's Labs Gets SEC Nod to Manufacture, Market Oral Semaglutide Tablets - Medical Dialogues · Medical Dialogues · Wed, 25 Mar 2026
7. Delhi High Court Permits Dr. Reddy’s To Manufacture Semaglutide Drug & Export To Other Countries Where... - Verdictum · Verdictum · Thu, 04 Dec 2025

Financial performance and recent trajectory

Dr Reddy's reported FY25 consolidated revenue of approximately ₹30,000 crore with EBITDA of ₹7,200 crore. EBITDA margin in the 23 to 25 percent range reflects the US generics mix and the operating leverage on the India domestic business. The Revlimid generic launch was a meaningful FY24-FY25 revenue and profit driver. R&D spend is approximately 8 to 10 percent of revenue.

Stock performance and shareholder context

Dr Reddy's (NSE: DRREDDY, BSE: 500124, NYSE: RDY) is a Nifty 50 constituent and has an ADR on the NYSE that provides US investor access. The Reddy family holds approximately 26 percent.

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

In US generics, principal competitors are Teva Pharmaceutical, Sandoz, Sun Pharma, and Aurobindo Pharma. In India domestic, Sun Pharma, Cipla, Mankind Pharma, and Torrent Pharma. In biosimilars, the principal competitors are Biocon, Reliance Life Sciences, Dr Reddy's itself, and global players Pfizer, Samsung Bioepis, Celltrion.

Key risks

US FDA inspection findings; complex-generic and biosimilar development execution; patent expiry timing; INR-USD volatility; India domestic price regulation; emerging markets currency volatility.

Outlook

Strong outlook on the US complex-generics and biosimilars pipeline through FY30. The India domestic business remains the stable base. For new entrants in API manufacturing or generic formulations, Dr Reddy's sets the benchmark for regulatory excellence and capital allocation discipline.

KAMRIT point of view

Building or competing with Dr?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Dr and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 2 related project reports → Book a scoping call

Related KAMRIT project reports

These reports use Dr Reddy's Laboratories Limited in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.